A mid-term follow-up with a lung ultrasonographic score correlates with the severity of COVID-19 acute phase
Abstract Lung ultrasound (LUS) has rapidly emerged in COVID-19 diagnosis and for the follow-up during the acute phase. LUS is not yet used routinely in lung damage follow-up after COVID-19 infection. We investigated the correlation between LUS score, and clinical and laboratory parameters of severity of SARS-COV-2 damage during hospitalization and at follow-up visit. Observational retrospective study including all the patients discharged from the COVID-19 wards, who attended the post-COVID outpatient clinic of the IRCCS Policlinico San Matteo in April–June 2020. 115 patients were enrolled. Follow-up visits with LUS score measurements were at a median of 38 days (IQR 28–48) after discharge. LUS scores were associated with the length of hospitalization (p < 0.001), patients’ age (p = 0.036), use of non-invasive ventilation (CPAP p < 0.001 or HFNC p = 0.018), administration of corticosteroids therapy (p = 0.030), and laboratory parameters during the acute phase (WBC p < 0.001, LDH p < 0.001, CRP p < 0.001, D-dimer p = 0.008, IL-6 p = 0.045), and inversely correlated with lymphocyte count (p = 0.007). We found correlation between LUS score and both LDH (p = 0.001) and the antibody anti-SARS-CoV-2 titers (p value = 0.008). Most of these finding were confirmed by dichothomizing the LUS score (≤ 9 or > 9 points). We found a significantly higher LUS score at the follow-up in the patients with persistent dyspnea (7.00, IQR 3.00–11.00) when compared to eupnoeic patients (3.00, IQR 0–7.00 p < 0.001). LUS score at follow-up visit correlates with more severe lung disease. These findings support the hypothesis that ultrasound could be a valid tool in the follow-up medium-term COVID-19 lung damage..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Internal and emergency medicine - 18(2022), 1 vom: 05. Dez., Seite 163-168 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Perrone, Tiziano [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI) 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11739-022-03144-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2133612785 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2133612785 | ||
| 003 | DE-627 | ||
| 005 | 20230506152135.0 | ||
| 007 | tu | ||
| 008 | 230506s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11739-022-03144-0 |2 doi | |
| 035 | |a (DE-627)OLC2133612785 | ||
| 035 | |a (DE-He213)s11739-022-03144-0-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Perrone, Tiziano |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A mid-term follow-up with a lung ultrasonographic score correlates with the severity of COVID-19 acute phase |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI) 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Lung ultrasound (LUS) has rapidly emerged in COVID-19 diagnosis and for the follow-up during the acute phase. LUS is not yet used routinely in lung damage follow-up after COVID-19 infection. We investigated the correlation between LUS score, and clinical and laboratory parameters of severity of SARS-COV-2 damage during hospitalization and at follow-up visit. Observational retrospective study including all the patients discharged from the COVID-19 wards, who attended the post-COVID outpatient clinic of the IRCCS Policlinico San Matteo in April–June 2020. 115 patients were enrolled. Follow-up visits with LUS score measurements were at a median of 38 days (IQR 28–48) after discharge. LUS scores were associated with the length of hospitalization (p < 0.001), patients’ age (p = 0.036), use of non-invasive ventilation (CPAP p < 0.001 or HFNC p = 0.018), administration of corticosteroids therapy (p = 0.030), and laboratory parameters during the acute phase (WBC p < 0.001, LDH p < 0.001, CRP p < 0.001, D-dimer p = 0.008, IL-6 p = 0.045), and inversely correlated with lymphocyte count (p = 0.007). We found correlation between LUS score and both LDH (p = 0.001) and the antibody anti-SARS-CoV-2 titers (p value = 0.008). Most of these finding were confirmed by dichothomizing the LUS score (≤ 9 or > 9 points). We found a significantly higher LUS score at the follow-up in the patients with persistent dyspnea (7.00, IQR 3.00–11.00) when compared to eupnoeic patients (3.00, IQR 0–7.00 p < 0.001). LUS score at follow-up visit correlates with more severe lung disease. These findings support the hypothesis that ultrasound could be a valid tool in the follow-up medium-term COVID-19 lung damage. | ||
| 650 | 4 | |a Imaging | |
| 650 | 4 | |a Lung | |
| 650 | 4 | |a Radiology | |
| 650 | 4 | |a Viral infection | |
| 650 | 4 | |a Ultrasound | |
| 700 | 1 | |a Falaschi, Francesco |4 aut | |
| 700 | 1 | |a Meloni, Federica |4 aut | |
| 700 | 1 | |a Ballesio, Alessia |4 aut | |
| 700 | 1 | |a Sabatini, Umberto |4 aut | |
| 700 | 1 | |a Lenti, Marco Vincenzo |4 aut | |
| 700 | 1 | |a Melazzini, Federica |4 aut | |
| 700 | 1 | |a Lettieri, Sara |4 aut | |
| 700 | 1 | |a Novati, Stefano |4 aut | |
| 700 | 1 | |a Cutti, Sara |4 aut | |
| 700 | 1 | |a Marioli, Carola Maria |4 aut | |
| 700 | 1 | |a Klersy, Catherine |4 aut | |
| 700 | 1 | |a Bruno, Raffaele |4 aut | |
| 700 | 1 | |a Oltrona Visconti, Luigi |4 aut | |
| 700 | 1 | |a Di Sabatino, Antonio |0 (orcid)0000-0002-0302-8645 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal and emergency medicine |d Springer International Publishing, 2006 |g 18(2022), 1 vom: 05. Dez., Seite 163-168 |w (DE-627)579836665 |w (DE-600)2454173-4 |w (DE-576)429794649 |x 1828-0447 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:1 |g day:05 |g month:12 |g pages:163-168 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11739-022-03144-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 1 |b 05 |c 12 |h 163-168 | ||